Venturi Wealth Management LLC Purchases Shares of 1,250 Insmed Incorporated (NASDAQ:INSM)

Venturi Wealth Management LLC purchased a new position in shares of Insmed Incorporated (NASDAQ:INSM) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 1,250 shares of the biopharmaceutical company’s stock, valued at approximately $86,000.

Several other hedge funds have also recently made changes to their positions in the business. V Square Quantitative Management LLC grew its stake in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares during the period. Spire Wealth Management acquired a new position in Insmed during the 4th quarter valued at about $47,000. Blue Trust Inc. increased its holdings in Insmed by 2,348.8% during the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 1,879 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Insmed in the third quarter worth approximately $133,000. Finally, Avior Wealth Management LLC purchased a new stake in shares of Insmed in the fourth quarter worth approximately $157,000.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on INSM shares. Truist Financial upped their price target on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a report on Friday. JPMorgan Chase & Co. upped their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Morgan Stanley increased their target price on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Finally, Wells Fargo & Company increased their price objective on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $91.00.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 3,344 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the sale, the insider now directly owns 102,766 shares in the company, valued at approximately $6,773,307.06. The trade was a 3.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 18,322 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total value of $1,471,439.82. Following the completion of the transaction, the chief financial officer now owns 118,863 shares of the company’s stock, valued at approximately $9,545,887.53. This represents a 13.36 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 532,207 shares of company stock worth $41,400,465. 4.60% of the stock is owned by corporate insiders.

Insmed Price Performance

Insmed stock opened at $81.06 on Monday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The business’s 50 day simple moving average is $74.29 and its 200 day simple moving average is $73.61. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91. The company has a market cap of $14.50 billion, a price-to-earnings ratio of -14.50 and a beta of 1.11.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Sell-side analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.